When treatment options narrowed
KFF Health News reported that Doppelt’s lung cancer had spread to her brain despite earlier treatment. A trial exclusion further narrowed her options. Her son, Max, eventually travelled to Shanghai to obtain sunvozertinib, developed by China’s Dizal Pharmaceutical. This was a family member’s medicine-access journey; the reporting does not describe Debbie travelling to China for hospital treatment.
Why China became part of the answer
Speaking to the South China Morning Post, Max expressed gratitude for the Chinese drug development that he believed had helped his mother. The newspaper’s 23 October report described an unusual access gap: the medicine had received US approval but had remained difficult to obtain commercially there. It also reported AstraZeneca’s plans to start selling it. That historical obstacle should not be read as a statement that the drug remains unavailable today.
What the drug says about Chinese cancer innovation
The FDA granted sunvozertinib accelerated approval on 2 July 2025 for a defined group of adults with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations, after progression on platinum chemotherapy. In the 85-patient efficacy population, the confirmed response rate was 46%, with a median response duration of 11.1 months. These are tumour-response results, not a cure rate or proof of longer survival.
The FDA also lists significant risks, including lung inflammation, gastrointestinal, skin and eye adverse effects. The advance is a targeted option for a particular cancer subtype, rather than a treatment for every lung cancer.
The progress reported, and its limits
KFF described disease control about 19 months after Doppelt started the drug, alongside radiation and dose adjustments. It also reported another patient whose cancer progressed on the same medicine. Neither experience establishes what a different patient’s outcome would be.
China Care perspective
What this case helps us understand
China’s contribution in this story is a new drug developed for a specific molecular form of lung cancer. The family’s experience brings the laboratory, the regulator and the supply chain into the same picture: scientific progress becomes useful when a patient can actually obtain the medicine. That is one practical way Chinese medical innovation is becoming part of care overseas.
Sources & further reading
Original reporting belongs to the publishers below. This article is an independently written account based on those sources, with editorial interpretation identified above.
- South China Morning PostChinese cancer drug on sale in US after Americans travel to buy it (opens in a new tab)
Accessible report excerpt; interview attribution and commercial-access update
- KFF Health NewsAs Politicians Argue About China, US Patients Find Cutting-Edge Treatment There (opens in a new tab)
Patient history, family travel and reported response
- US Food and Drug AdministrationFDA grants accelerated approval to sunvozertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (opens in a new tab)
Approved indication, efficacy population, response results and risks
China Care did not provide the care described. This story does not imply a relationship with the patient or hospital, or that China Care can arrange the same treatment. Individual outcomes do not predict other patients’ results. This is editorial information, not medical advice.
Published by China Care on 29 October 2026. Patient experiences and treatment access reflect the dates of the cited reporting.